Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Characterization of cell lines.
  • Fig. S2. Effect of PEPDG278D on nuclear contents of HER2 and EGFR and intracellular PEPD-p53 complex.
  • Fig. S3. HER2-binding and other activities of PEPDG278D with or without comparison to Ttzm or pertuzumab.
  • Fig. S4. Effect of PEPDG278D on expression of p-VEGFR-1, VEGFR-1, IGF1R, and MET, and on IGF1 stimulation of IGF1R.
  • Fig. S5. Effect of EP on total plasma concentrations of endogenous PEPD and exogenously administered PEPDG278D.
  • Fig. S6. NRG-1 expression in cell lines and effect of PEPDG278D on NRG-1 stimulation of HER3, AKT, and cell proliferation.
  • Fig. S7. Tumor histology, response of EGFR and HER2 to PEPDG278D in normal tissues, and their expression in normal and tumor tissues.
  • Fig. S8. Effects of PEPDG278D and paclitaxel alone or in combination on HER2, CDC2, and p21 in JIMT-1 cells.
  • Fig. S9. A graphic presentation of PEPDG278D targeting Ttzm-resistant HER2-BC cells in two sequential phases.
  • Reference (54)

[Download PDF]

Other Supplementary Material for this manuscript includes the following: